



Liquid Biopsy: Current Status and New Challenges

Guest Editors:

Dr. María Jose Serrano

Dr. Carmen Garrido Navas

Dr. Valeria C. Denninghoff

Deadline for manuscript
submissions:

closed (31 August 2023)

Message from the Guest Editors

Liquid biopsy is a critical strategic main in precision medicine. Its use allows us to monitor the patient's evolution in real-time. The most crucial role of the LBs is their use as prognostic and predictive markers in different types of tumors. LBs have been accepted as prognostic and predictive markers in numerous solid tumors. Therefore, their use in clinical routine has promoted the need to improve the methodologies for analyzing these markers. However most LBs show a common characteristic, "minimal biological amounts" to work, whether we are talking about CTCs, ctDNA, or tumor educated platelets, which make their use difficult. New methodologies applied to analyze LBs have emerged to solve these limitations. Both allow us to obtain accurate results using minimal samples. More importantly, these advances promote the use of the LBs in other fields beyond metastatic cancer and cancer. The detection of minimal residual disease to predict the risk of relapse in solid tumors is one of the main challenges of using LB. Also, LBs are now open to their use as diagnostic markers in those non-tumoral diseases associated with cancer risk and in cancer interception.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)